文献速递烧伤创面修复

氨甲环酸在烧伤手术中的应用:系统综述与Meta分析

Tranexamic acid in burn surgery: A systematic review and meta-analysis.
PubMed 文献 · Burns · 2023-05-10

该研究纳入8篇论文,采用随机效应模型Meta分析,评估氨甲环酸对烧伤手术结局的影响。与对照组相比,氨甲环酸显著减少总失血量、失血量与烧伤总面积比、单位面积失血量及术中输血患者数,静脉血栓栓塞事件和死亡率无显著差异。

要点

  • 与对照组相比,氨甲环酸显著减少烧伤手术总失血量(MD=-192.44,95%CI -297.73至-87.14,P=0.0003)。
  • 氨甲环酸组术中输血患者数较对照组减少(RD=-0.16,95%CI -0.32至-0.01,P=0.04)。
  • 静脉血栓栓塞事件(RD=0.00,95%CI -0.03至0.03,P=0.98)和死亡率(RD=0.00,95%CI -0.03至0.04,P=0.86)无显著差异。

核心结论

  • 氨甲环酸可能是一种药物干预措施,可减少烧伤手术中的失血和输血,且不增加静脉血栓栓塞事件或死亡风险。

研究设计与样本

  • 系统综述与Meta分析,纳入8篇论文,采用随机效应模型分析结局。

主要发现

  • 与对照组相比,氨甲环酸显著减少总失血量(MD=-192.44,95%CI -297.73至-87.14,P=0.0003)。
  • 与对照组相比,氨甲环酸显著减少失血量与烧伤总面积比(MD=-7.31,95%CI -10.77至-3.84,P<0.0001)。
  • 与对照组相比,氨甲环酸显著减少单位面积失血量(MD=-0.59,95%CI -0.97至-0.20,P=0.003)。
  • 与对照组相比,氨甲环酸组术中输血患者数减少(RD=-0.16,95%CI -0.32至-0.01,P=0.04)。
  • 静脉血栓栓塞事件(RD=0.00,95%CI -0.03至0.03,P=0.98)和死亡率(RD=0.00,95%CI -0.03至0.04,P=0.86)无显著差异。

关键数值与推荐

  • 总失血量:氨甲环酸组较对照组MD=-192.44(95%CI -297.73至-87.14,P=0.0003)。
  • 失血量与烧伤总面积比:氨甲环酸组较对照组MD=-7.31(95%CI -10.77至-3.84,P<0.0001)。
  • 单位面积失血量:氨甲环酸组较对照组MD=-0.59(95%CI -0.97至-0.20,P=0.003)。
  • 术中输血患者数:氨甲环酸组较对照组RD=-0.16(95%CI -0.32至-0.01,P=0.04)。
  • 静脉血栓栓塞事件:氨甲环酸组与对照组RD=0.00(95%CI -0.03至0.03,P=0.98);死亡率:RD=0.00(95%CI -0.03至0.04,P=0.86)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burn injury causes a coagulopathy that is poorly understood. After severe burns, significant fluid losses are managed by aggressive resuscitation that can lead to hemodilution. These injuries are managed by early excision and grafting, which can cause significant bleeding and further decrease blood cell concentration. Tranexamic acid (TXA) is an anti-fibrinolytic that has been shown to reduce surgical blood losses; however, its use in burn surgery is not well established. We performed a systematic review and meta-analysis to investigate the influence TXA may have on burn surgery outcomes. Eight papers were included, with outcomes considered in a random-effects model meta-analysis. Overall, when compared to the control group, TXA significantly reduced total volume blood loss (mean difference (MD) = -192.44; 95% confidence interval (CI) = -297.73 to - 87.14; P = 0.0003), the ratio of blood loss to burn injury total body surface area (TBSA) (MD = -7.31; 95% CI = -10.77 to -3.84; P 0.0001), blood loss per unit area treated (MD = -0.59; 95% CI = -0.97 to -0.20; P = 0.003), and the number of patients receiving a transfusion intraoperatively (risk difference (RD) = -0.16; 95% CI = -0.32 to - 0.01; P = 0.04). Additionally, there were no noticeable differences in venous thromboembolism (VTE) events (RD = 0.00; 95% CI = -0.03 to 0.03; P = 0.98) and mortality (RD = 0.00; 95% CI = -0.03 to 0.04; P = 0.86). In conclusion, TXA can potentially be a pharmacologic intervention that reduces blood losses and transfusions in burn surgery without increasing the risk of VTE events or mortality.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Fijany AJ, Givechian KB, Zago I, et al. Tranexamic acid in burn surgery: A systematic review and meta-analysis. Burns. 2023. PMID: 37268542. doi:10.1016/j.burns.2023.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。